# Pizarra — PT-pseudo_249def42388a (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_249def42388a
Task: 1

Encounter: Urology - outpatient on 20 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 78-year-old male
  - PSA: 7.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.236 ng/mL²
  - PSA velocity: 0.84 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 32.25 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.82135016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.6 ng/mL. PI-RADS 5. PSAD 0.24. Prostate volume 32 mL. DRE nodus. csPCa 0.82.

Vitals: weight 104 kg, height 190 cm, BMI 28.8, BP 136/96 mmHg, HR 64 bpm. Smoking: Current smoker (29 pack-yr).

Chief complaint: Persistent PSA elevation alongside recent multiparametric MRI results prompted this clinical evaluation.

History: Now 78 years old, this widowed civil engineer recently retired and moved to the region half a year ago. He shares a home with his sister, while his adult son handles daily logistics and serves as his lasting power of attorney. His prior biopsy bucket remains "None". Lower urinary tract complaints are entirely absent, yielding an IPSS score of zero, and he explicitly denies pelvic discomfort or blood in the urine. His medical background includes well-regulated type 2 diabetes, currently treated with empagliflozin under quarterly diabetes nurse supervision. A substantial 29 pack-yr smoking history is noted, alongside a moderate alcohol consumption pattern of twelve units weekly. He swims once a week to stay fit. Stable osteoarthritis in his right knee is managed with paracetamol, and he recalls a minor appendectomy during his twenties. Otherwise, he reports feeling generally robust.

Physical examination: DRE — texture: firm with a discrete Nodus localized to the left peripheral zone; asymmetry: clearly present. General examination remains unremarkable, recording a blood pressure of 136/96 mmHg, a heart rate of 64 bpm, and a body mass index of 28.8. No abdominal masses or peripheral lymphadenopathy are detected.

Patient info: civil engineer; Widowed; Recently relocated; lives with sister.
Next of kin: Adult son (acts as caregiver, lasting power of attorney).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Diabetes nurse — quarterly review.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.69 +/- 0.10   (95% CI 0.50-0.88)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.90 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant immediate action?
  - previous_notes (get_previous_notes) -> What was the prior management context and agreed-upon surveillance pathway?

This case hinges on the detailed findings from the mpMRI and the trajectory of the PSA, as the statistical prior and protocol only provide a general suggestion based on the visible panel. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which excludes the prose of the mpMRI report, the PSA trajectory, and the previous notes. Specifically, it did not account for the PI-RADS 5 score, the PSA velocity of 0.84 ng/mL/yr, or the specific context of the prior biopsy status ("None").

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a probability of 0.69 +/- 0.10. This suggestion could be wrong because the high aleatoric uncertainty (H=0.90) indicates the model struggles with this case's data distribution. Furthermore, the protocol states biopsy is indicated for PI-RADS $\ge 3$, but the prior did not weigh the high PSA velocity (0.84 ng/mL/yr) or the high csPCa probability (0.82135016), which might suggest a need for a different management pathway than a simple guideline match.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant immediate action?
previous_notes - What was the prior management context and agreed-upon surveillance pathway?
previous_notes - What was the prior management context and agreed-upon surveillance pathway?

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Catharina Ziekenhuis, Eindhoven | 28 Jan 2025 | Multiparametric MRI Prostate
The mpMRI report identifies a PI-RADS: 5 lesion in the left peripheral zone (base/mid), approximately 18 mm. It notes that extracapsular spread and seminal vesicle involvement are absent.

get_psa_trend
The PSA trend shows a significant rise from 0.6 ng/mL in Jul 2022 to 7.6 ng/mL in Feb 2025, indicating a rising trajectory.

get_previous_notes
The previous notes from Mar 2023 document a steady rise in PSA from 4.3 ng/mL (Mar 2023) to 5.9 ng/mL (Jun 2024), with diabetes care being reassessed. No prior biopsy result or specific surveillance protocol agreement is detailed beyond general follow-up.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS score of 5 lesion in the left peripheral zone (base/mid), approximately 18 mm.
- PSA trend: Significant rise from 0.6 ng/mL (Jul 2022) to 7.6 ng/mL (Feb 2025).

AGAINST sampling this patient now:
- previous_notes: No specific prior biopsy grade or established active surveillance protocol was documented.

WHERE THIS LEANS
The evidence strongly supports immediate biopsy due to the high-risk PI-RADS 5 finding and the concerning PSA velocity.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 5 finding from the MRI and the significant PSA trend, strongly supports the guideline criterion for biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The PI-RADS 5 finding from the mpMRI report is decisive, aligning with the guideline criterion for biopsy when PI-RADS is 3 or higher. This finding was reinforced by the significant PSA trend, which was retrieved as evidence. The statistical prior also suggested biopsy, and the retrieved evidence confirmed the clinical indication.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
